{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:38:12Z","timestamp":1792755492000,"version":"4.5.0"},"reference-count":43,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Ophthalmology"],"published-print":{"date-parts":[[2026,11,17]]},"DOI":"10.1080\/08820538.2025.2606981","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T03:50:52Z","timestamp":1766634652000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Outcomes of Teprotumumab and Tocilizumab in Thyroid Eye Disease: The First Retrospective Study from the United Arab Emirates and Gulf Region of the Middle East"],"prefix":"10.1080","volume":"41","author":[{"given":"Habibullah","family":"Eatamadi","sequence":"first","affiliation":[{"name":"Sheikh Khalifa Medical City","place":["Abu Dhabi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443364"},{"issue":"4","key":"e_1_3_3_3_1","first-page":"238","article-title":"Combined immunosuppression and radiotherapy in thyroid eye disease","volume":"24","author":"Marcocci C","year":"2001","unstructured":"Marcocci C, Bartalena L, Bogazzi F, et al. Combined immunosuppression and radiotherapy in thyroid eye disease. J Endocrinol Invest. 2001;24(4):238\u2013242.","journal-title":"J Endocrinol Invest"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0666"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2389"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.038"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03143-4"},{"issue":"4","key":"e_1_3_3_11_1","first-page":"dgz271","article-title":"Long-term efficacy of tocilizumab in moderate-to-severe Graves\u2019 orbitopathy","volume":"105","author":"P\u00e9rez-Moreiras JV","year":"2020","unstructured":"P\u00e9rez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Long-term efficacy of tocilizumab in moderate-to-severe Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2020;105(4):dgz271.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.73.8.639"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02230"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300487"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30485-7"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001631"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab374"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002241"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.017"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2025.2503911"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.92.PS3-24-05"},{"key":"e_1_3_3_23_1","first-page":"25","article-title":"Long-term outcomes of teprotumumab in thyroid eye disease","volume":"238","author":"Sears CM","year":"2022","unstructured":"Sears CM, Azad AD, Carter KD, et al. Long-term outcomes of teprotumumab in thyroid eye disease. Am J Ophthalmol. 2022;238:25\u201332.","journal-title":"Am J Ophthalmol"},{"key":"e_1_3_3_24_1","first-page":"145897","article-title":"Efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and meta-analysis","volume":"16","author":"Boutzios G","year":"2025","unstructured":"Boutzios G, Duntas LH, Doumas C, et al. Efficacy and safety of intravenous tocilizumab to treat Graves\u2019 ophthalmopathy: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2025;16:145897.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2020.07.020"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2023.0167"},{"key":"e_1_3_3_27_1","unstructured":"ClinicalTrials.gov. A study of satralizumab in thyroid eye disease (SatraGO-1) (NCT05987423); A study of satralizumab in thyroid eye disease (SatraGO-2) (NCT06106828); A study of IL-6 receptor blockade in thyroid eye disease (NCT01297699). October 2025. https:\/\/clinicaltrials.gov\/"},{"key":"e_1_3_3_28_1","volume-title":"Presented at ASOPRS Fall Scientific Symposium 2025","author":"Brice\u00f1o CA","year":"2025","unstructured":"Brice\u00f1o CA, Ortiz-P\u00e9rez S, et al. Primary results of the phase 3 SatraGO-1 and SatraGO-2 trials: efficacy and safety of satralizumab in thyroid eye disease. Presented at ASOPRS Fall Scientific Symposium 2025; 2025; Orlando, USA: Genentech\/Guideline Central (preliminary data)."},{"issue":"1","key":"e_1_3_3_29_1","first-page":"128","article-title":"Insights into the role of IGF-1R in thyroid eye disease","volume":"35","author":"Kazim M","year":"2021","unstructured":"Kazim M, Goldberg RA, Smith TJ. Insights into the role of IGF-1R in thyroid eye disease. Eye (Lond). 2021;35(1):128\u2013136.","journal-title":"Eye (Lond)"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab150"},{"issue":"3","key":"e_1_3_3_31_1","first-page":"189","article-title":"Diplopia outcomes after teprotumumab therapy for thyroid eye disease","volume":"43","author":"Davis JB","year":"2023","unstructured":"Davis JB, Mudalegundi S, Henderson AD, Carey AR. Diplopia outcomes after teprotumumab therapy for thyroid eye disease. J Neuro-Ophthalmol. 2023;43(3):189\u2013196.","journal-title":"J Neuro-Ophthalmol"},{"issue":"4","key":"e_1_3_3_32_1","first-page":"338","article-title":"Strabismus surgery outcomes following teprotumumab treatment","volume":"39","author":"Hilliard LM","year":"2023","unstructured":"Hilliard LM, Pruett J, Donahue SP, et al. Strabismus surgery outcomes following teprotumumab treatment. Ophthal Plast Reconstr Surg. 2023;39(4):338\u2013343.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002611"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000002839"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2009.0283"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae028"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.01.007"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad003"},{"issue":"1","key":"e_1_3_3_39_1","first-page":"1","article-title":"The role of orbital imaging in thyroid eye disease","volume":"59","author":"Kikkawa DO","year":"2019","unstructured":"Kikkawa DO, Cruz RC, Korn BS. The role of orbital imaging in thyroid eye disease. Int Ophthalmol Clin. 2019;59(1):1\u201310.","journal-title":"Int Ophthalmol Clin"},{"issue":"6","key":"e_1_3_3_40_1","first-page":"742","article-title":"Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease","volume":"41","author":"Ting MA","year":"2022","unstructured":"Ting MA, Ozzello DJ, Topilow NJ, et al. Differential effects of teprotumumab treatment based on fat-to-muscle ratio in patients with thyroid eye disease. Orbit. 2022;41(6):742\u2013747.","journal-title":"Orbit"},{"issue":"3","key":"e_1_3_3_41_1","first-page":"98","article-title":"Thyroid hormone and gamma-aminobutyric acid (GABA) interactions: from neuroendocrine control to clinical implications","volume":"17","author":"Arrigo T","year":"2006","unstructured":"Arrigo T, Salerno M, De Luca F. Thyroid hormone and gamma-aminobutyric acid (GABA) interactions: from neuroendocrine control to clinical implications. Trends Endocrinol Metab. 2006;17(3):98\u2013104.","journal-title":"Trends Endocrinol Metab"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1220929"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.1.29"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.012451"}],"container-title":["Seminars in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08820538.2025.2606981","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/08820538.2025.2606981","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/08820538.2025.2606981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:46:27Z","timestamp":1792752387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/08820538.2025.2606981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,11,17]]}},"alternative-id":["10.1080\/08820538.2025.2606981"],"URL":"https:\/\/doi.org\/10.1080\/08820538.2025.2606981","relation":{},"ISSN":["0882-0538","1744-5205"],"issn-type":[{"value":"0882-0538","type":"print"},{"value":"1744-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isio20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isio20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}